Four biopharma companies are pooling some of their chemical data and making it public for the first time as part of the pioneering stage of a European effort to reduce the need for animal testing in drug development.
Hesperos Inc.'s human-on-a-chip in vitro model for the first time successfully predicted human response to two drugs. The multi-organ model provided new insight into the drugs' cardiotoxic effects in a study published in Nature Scientific Reports. The Orlando, Fla.-based company also recently demonstrated that its model could simultaneously measure cancer drug efficacy and off-target toxicity without animal models or human testing.
